SCHEMBL7645530

SCHEMBL7645530

CCc1c(C(=O)C(N)=O)c2c(C(=O)C(=O)O)nc(C)cn2c1Cc1ccc(F)cc1

nearest known ligand 0.48

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PLA2G1B P04054 17/20 0.48
PLA2G2A P14555 4/20 0.42
PLA2G2E Q9NZK7 2/20 0.39
PLA2G5 P39877 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7616781 0.89 PLA2G1B (0.47) PLA2G1BPLA2G2A
SCHEMBL7641251 0.86 PLA2G1B (0.58) PLA2G1BPLA2G2APLA2G2EPLA2G5
SCHEMBL7192247 0.84 PLA2G1B (0.57) PLA2G1BPLA2G2APLA2G2EPLA2G5
SCHEMBL7754878 0.81 PLA2G1B (0.45) PLA2G1BPLA2G2APLA2G2EPLA2G5
SCHEMBL7641632 0.80 PLA2G1B (0.54) PLA2G1BPLA2G2APLA2G2EPLA2G5
SCHEMBL13888714 0.80 PLA2G1B (0.42) PLA2G1BPLA2G2A
SCHEMBL13888553 0.78 PLA2G1B (0.59) PLA2G1BPLA2G2APLA2G2EPLA2G5
SCHEMBL7643172 0.78 PLA2G2A (0.51) PLA2G1BPLA2G2APLA2G2EPLA2G5
SCHEMBL14394327 0.78 PLA2G1B (0.43) PLA2G1BPLA2G2APLA2G2EPLA2G5
SCHEMBL7647147 0.78 PLA2G1B (0.55) PLA2G1BPLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1265607-A2 METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA 2 INHIBITORS ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
WO-2001066111-A1 COMPOSITIONS CONTAINING POTENTIAL SPLA2 INHIBITORS FOR THE TREATMENT OF PAIN ELI LILLY AND COMPANY (US) 2001-09-13 WO disclosed
WO-2001066110-A2 METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 2001-09-13 WO disclosed
WO-2001055108-A2 USE OF SPL A2 INHIBITORS FOR THE TREATMENT OF INFLAMMATION ELI LILLY AND COMPANY (US) 2001-08-02 WO disclosed